Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - multiple myeloma - antineoplastična sredstva - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - gripa, človek - cepiva - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - bolezen tipa ii za shranjevanje glikogena - drugi zdravljene bolezni prebavil in presnove izdelki, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - imunosupresivi - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningokokni - cepiva - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - imunski sera in imunoglobulini, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi b.v. - alglukozidaza alfa - bolezen tipa ii za shranjevanje glikogena - drugi zdravljene bolezni prebavil in presnove izdelki, - myozyme je indiciran za dolgoročno encimsko nadomestno zdravljenje (ert) pri bolnikih s potrjeno diagnozo pompejeve bolezni (pomanjkanje kisline-α-glukozidaze). pri bolnikih s poznim nastopom pompe bolezni dokazov o učinkovitosti, je omejeno.

Evropska unija - slovenščina - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloksetin - diabetične nevropatije - psychoanaleptics, - zdravljenje diabetične periferne nevropatske bolečine. ariclaim je navedeno v odrasli.

Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan dura gmbh - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - antitrombotična sredstva - clopidogrel je navedeno pri odraslih za preprečevanje atherothrombotic dogodkov v:bolnike, ki trpijo za miokardni infarkt (od nekaj dni do manj kot 35 dni), ischaemic kap (od 7 dni do manj kot 6 mesecev) ali sedež periferne arterijske bolezni.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pfizer europe ma eeig - bazedoksifen - osteoporoza, postmenopavz - spolni hormoni in zdravila genitalni sistem, - zdravilo conbriza je indicirano za zdravljenje postmenopavzalne osteoporoze pri ženskah pri povečanem tveganju zloma. dokazano je bilo znatno zmanjšanje incidence zlomov vretenc; učinkovitost zloma kolka ni bila ugotovljena. pri določanju izbiro conbriza ali drugih terapij, vključno z oestrogens, za posameznika postmenopausal ženska, bi bilo treba preučiti, simptomov menopavze, vplivi na maternice in dojk tkiv, in žilnega tveganja in koristi.